Mizielska, A.; Dziechciowska, I.; Szczepański, R.; Cisek, M.; Dąbrowska, M.; Ślężak, J.; Kosmalska, I.; Rymarczyk, M.; Wilkowska, K.; Jacczak, B.;
et al. Doxorubicin and Cisplatin Modulate miR-21, miR-106, miR-126, miR-155 and miR-199 Levels in MCF7, MDA-MB-231 and SK-BR-3 Cells That Makes Them Potential Elements of the DNA-Damaging Drug Treatment Response Monitoring in Breast Cancer Cells—A Preliminary Study. Genes 2023, 14, 702.
https://doi.org/10.3390/genes14030702
AMA Style
Mizielska A, Dziechciowska I, Szczepański R, Cisek M, Dąbrowska M, Ślężak J, Kosmalska I, Rymarczyk M, Wilkowska K, Jacczak B,
et al. Doxorubicin and Cisplatin Modulate miR-21, miR-106, miR-126, miR-155 and miR-199 Levels in MCF7, MDA-MB-231 and SK-BR-3 Cells That Makes Them Potential Elements of the DNA-Damaging Drug Treatment Response Monitoring in Breast Cancer Cells—A Preliminary Study. Genes. 2023; 14(3):702.
https://doi.org/10.3390/genes14030702
Chicago/Turabian Style
Mizielska, Anna, Iga Dziechciowska, Radosław Szczepański, Małgorzata Cisek, Małgorzata Dąbrowska, Jan Ślężak, Izabela Kosmalska, Marta Rymarczyk, Klaudia Wilkowska, Barbara Jacczak,
and et al. 2023. "Doxorubicin and Cisplatin Modulate miR-21, miR-106, miR-126, miR-155 and miR-199 Levels in MCF7, MDA-MB-231 and SK-BR-3 Cells That Makes Them Potential Elements of the DNA-Damaging Drug Treatment Response Monitoring in Breast Cancer Cells—A Preliminary Study" Genes 14, no. 3: 702.
https://doi.org/10.3390/genes14030702
APA Style
Mizielska, A., Dziechciowska, I., Szczepański, R., Cisek, M., Dąbrowska, M., Ślężak, J., Kosmalska, I., Rymarczyk, M., Wilkowska, K., Jacczak, B., Totoń, E., Lisiak, N., Kopczyński, P., & Rubiś, B.
(2023). Doxorubicin and Cisplatin Modulate miR-21, miR-106, miR-126, miR-155 and miR-199 Levels in MCF7, MDA-MB-231 and SK-BR-3 Cells That Makes Them Potential Elements of the DNA-Damaging Drug Treatment Response Monitoring in Breast Cancer Cells—A Preliminary Study. Genes, 14(3), 702.
https://doi.org/10.3390/genes14030702
